Post-Surgical Recovery Annual Evaluation Checklist

Why a Formal Annual Evaluation Matters

A single post-operative discharge visit is not enough to catch every complication. Annual evaluation provides a systematic checkpoint to identify delayed wound failure, functional decline, nutritional gaps, and psychological sequelae that standard 6-week follow-up appointments routinely miss.

The American College of Surgeons' National Surgical Quality Improvement Program (NSQIP) tracks 30-day outcomes in over 700 participating hospitals, yet data consistently show that many complications, including incisional hernia, chronic pain, and mood disorders, surface well beyond that 30-day window. [1] A structured 12-month checklist closes that surveillance gap.

The Scope of Post-Surgical Morbidity

Chronic post-surgical pain (CPSP) develops in 10 to 50% of patients, varying by procedure. Thoracotomy carries the highest CPSP risk at roughly 50%, while inguinal hernia repair sits closer to 10 to 12%. [2] These numbers matter because unaddressed pain at 12 months predicts long-term opioid dependence.

A 2021 systematic review in the BMJ covering 283,000 patients found that 6.2% required re-hospitalization within 12 months for a complication directly linked to the index procedure. [3] Annual evaluation catches a meaningful portion of these cases before they escalate.

Who Needs Annual Evaluation

Not every patient requires the same depth of review. A useful clinical stratification:

• Low-complexity elective surgery (laparoscopic cholecystectomy, hernia repair): one formal 12-month visit plus patient-reported outcome (PRO) survey.
• Moderate-complexity surgery (joint replacement, spinal fusion, bariatric): quarterly functional checks through 12 months, then annual thereafter.
• Major trauma or oncologic resection: annual evaluation for at minimum 5 years, coordinated with the specialty service.

The 12-Month Evaluation Checklist: Section by Section

Every component below maps to a validated tool, a guideline recommendation, or a primary-source dataset. Work through each domain systematically.

1. Wound and Tissue Integrity

Inspect the incision site for hypertrophic scarring, keloid formation, seroma, sinus tract, or mesh-related complications. The incidence of incisional hernia after midline laparotomy reaches 11 to 20% at 2 years if fascial closure technique is suboptimal. [4]

Document: scar width, palpable subcutaneous mass, skin hypersensitivity, and any drainage. Photograph the wound at each annual visit to enable objective longitudinal comparison.

Patients who received 503A-compounded BPC-157 or TB-500 off-label during the acute recovery phase should be asked whether they continued self-administration, since ongoing peptide use is common and may affect wound appearance and angiogenesis markers in animal models. [5]

2. Functional and Physical Capacity Assessment

Use the PROMIS Global Health Short Form (SF-10) or the SF-36 Physical Component Summary (PCS). Both are validated in surgical populations and take <5 minutes to complete. The minimum clinically important difference (MCID) for SF-36 PCS is 3 to 5 points. [6]

Gait speed <0.8 m/s at 12 months post-major surgery predicts 30-day re-admission with a sensitivity of 70% and specificity of 74% in patients over 65. [7] A simple 4-meter timed walk test belongs in every annual evaluation for patients over 60.

Strength testing (handgrip dynamometry) offers a quick proxy for whole-body lean mass. Normative values by sex and age are published by Dodds et al. (2014) in Age and Ageing. [8]

3. Laboratory Panel

A targeted panel balances clinical yield against cost. The following components are supported by guideline-level or cohort-level evidence:

| Test | Rationale | Guideline Source | |---|---|---| | CBC with differential | Detect chronic anemia, infection | NSQIP surveillance data [1] | | Comprehensive metabolic panel | Renal/hepatic function, electrolytes | Standard of care | | C-reactive protein (CRP) | Ongoing systemic inflammation | ESR/CRP as wound healing marker [9] | | Ferritin + serum iron | Iron deficiency common after GI surgery | ERAS Society guidelines [10] | | 25-OH Vitamin D | Deficiency impairs wound tensile strength | Endocrine Society guideline [11] | | HbA1c (if diabetic or pre-diabetic) | Glycemic control is the single strongest modifiable predictor of wound infection | ADA Standards of Care 2024 [12] | | Albumin / prealbumin | Nutritional status; albumin <3.5 g/dL = high surgical risk | ASPEN guidelines [13] | | Testosterone (total + free) | Low T accelerates sarcopenia post-major surgery | Bhasin et al., NEJM 2010 [14] |

Vitamin D sufficiency (serum 25-OH >30 ng/mL) is particularly important. A randomized controlled trial (N=210) published in the Journal of Bone and Mineral Research found that cholecalciferol supplementation of 2,000 IU/day improved wound tensile strength at 12 weeks post-surgery compared to placebo (P<0.05). [11]

4. Nutritional Assessment

Protein-calorie malnutrition affects up to 40% of patients at 12 months after major abdominal surgery and is strongly associated with delayed wound healing, impaired immune function, and reduced muscle mass. [13]

The Malnutrition Universal Screening Tool (MUST) takes under 3 minutes to administer and is endorsed by ASPEN and the British Dietetic Association. Scores of 2 or higher prompt dietitian referral.

Target protein intake for post-surgical recovery: 1.2 to 1.5 g/kg/day. Patients recovering from burns or large wound debridement may require up to 2 g/kg/day per ASPEN critical care guidelines. [13]

5. Pain and Analgesic Burden

Chronic post-surgical pain (CPSP) is formally defined as pain persisting beyond 3 months that was not present pre-operatively. The ICD-11 adopted this definition in 2022. At the 12-month annual visit, quantify pain using:

• Numeric Rating Scale (NRS) 0 to 10 at rest and with movement.
• Pain Catastrophizing Scale (PCS-13) if NRS >4.
• Current analgesic use: opioid morphine milligram equivalents (MME) per day.

A 2018 JAMA Surgery meta-analysis (45 trials, N=9,551) found that pre-operative pain sensitization, younger age, and female sex were the three strongest predictors of CPSP development, with odds ratios of 2.1, 1.6, and 1.4 respectively. [2]

Any patient on >90 MME/day at 12 months should receive a formal pain specialist referral per CDC Clinical Practice Guideline for Prescribing Opioids (2022). [15]

6. Psychological and Cognitive Assessment

Depression and anxiety affect 15 to 25% of post-surgical patients at 1 year. After cardiac surgery specifically, the rate of clinically significant depression at 12 months reaches 30 to 40% by some estimates. [16]

Administer the PHQ-9 for depression and the GAD-7 for anxiety at every annual visit. PHQ-9 >10 indicates moderate-to-severe depression and warrants formal psychiatric or psychological referral. GAD-7 >10 carries the same threshold for anxiety.

Cognitive function deserves attention after cardiac or major orthopedic surgery. Post-operative cognitive dysfunction (POCD) can persist beyond 12 months in 10 to 13% of patients over 60. [17] The Montreal Cognitive Assessment (MoCA, score <26/30) is a brief, validated screen.

Off-Label Peptide Use in Post-Surgical Recovery: BPC-157 and TB-500

This section covers one of the most frequently asked-about topics in telehealth surgical recovery consultations, the use of 503A-compounded peptides.

BPC-157: Mechanism and Evidence Level

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice. Animal studies show it promotes angiogenesis, upregulates growth hormone receptors, and accelerates tendon-to-bone healing. [5]

The evidence base remains almost entirely preclinical. A 2018 rodent study in the Journal of Physiology and Pharmacology found significantly accelerated Achilles tendon healing in BPC-157-treated rats compared to controls. [5] No phase III human RCT has been completed as of mid-2025, and the FDA has not approved BPC-157 for any indication.

Clinicians prescribing BPC-157 through 503A compounding pharmacies are operating fully off-label. Patients should be counseled that:

1. Long-term safety data in humans are absent.
2. Compounded peptide purity varies by pharmacy.
3. The FDA issued a memorandum in 2022 noting that certain peptides, including BPC-157, may not meet the criteria for 503A compounding exemption. [18]

TB-500 (Thymosin Beta-4): What the Data Show

Thymosin Beta-4 (TB-500) is a 43-amino-acid peptide that promotes actin polymerization, reduces inflammation, and may accelerate wound closure. Animal and in vitro data are promising. [19]

A 2010 phase II trial (N=93) tested Thymosin Beta-4 for pressure ulcer healing and found a non-significant trend toward faster closure (P = 0.09). No phase III trial has followed. [19] Like BPC-157, TB-500 is not FDA-approved and exists solely in the compounding pharmacy space.

How to Document Peptide Use in the Annual Evaluation

The following framework standardizes documentation for patients using off-label compounded peptides at the 12-month evaluation:

| Documentation Item | What to Record | |---|---| | Peptide name and dose | e.g., BPC-157 500 mcg SQ daily x 8 weeks | | Compounding pharmacy | Name, 503A vs. 503B status | | Start and stop dates | Duration of each course | | Subjective response | NRS pain change, wound appearance change | | Adverse events | Injection site reactions, systemic symptoms | | Lab changes | Any CRP, CBC, or metabolic changes temporally linked |

This documentation does not constitute an endorsement of these agents. It creates a clinical record that allows future physicians to contextualize healing timelines accurately.

Enhanced Recovery After Surgery (ERAS) Protocol Compliance Review

ERAS protocols are multimodal, evidence-based pathways designed to reduce physiologic stress from surgery. A 2019 Cochrane review of 14 RCTs found ERAS compliance reduced overall complications by 20 to 30% and shortened hospital stay by 1.1 days (95% CI 0.8 to 1.4 days). [20]

At the annual evaluation, review ERAS compliance across three phases:

Pre-operative Phase Adherence

• Was carbohydrate loading administered within 2 hours pre-op?
• Was multimodal analgesia (acetaminophen + NSAIDs + regional block) in the plan?
• Was nutritional optimization (albumin >3.5 g/dL) confirmed before elective cases?

Patients who did not receive pre-operative nutritional optimization show significantly higher 12-month complication rates. The ERAS Society's guideline on colonic surgery states, "Nutritional support should be initiated if oral intake is inadequate for more than 7 days perioperatively." [10]

Intra-operative Phase Adherence

• Was goal-directed fluid therapy used?
• Was normothermia maintained (core temp >36°C)?
• Was antibiotic prophylaxis timed within 60 minutes of incision?

Post-operative Phase Adherence

• Was early mobilization (within 6 to 12 hours of surgery) achieved?
• Was opioid-sparing analgesia maintained through discharge?
• Was nasogastric decompression avoided?

Each missed ERAS element represents a recoverable risk factor. Even at 12 months, identifying which elements were omitted helps explain current functional deficits and guides rehabilitation planning.

Glycemic Control and Wound Healing

Hyperglycemia is the single most consistently modifiable predictor of surgical site infection and delayed wound healing. The ADA Standards of Medical Care in Diabetes 2024 states: "Perioperative glucose targets of 140 to 180 mg/dL are recommended for most critically ill and non-critically ill surgical patients." [12]

At the annual evaluation, check HbA1c in any patient with a pre-operative diagnosis of diabetes or pre-diabetes. An HbA1c >8% at 12 months should prompt endocrinology co-management.

A prospective cohort study (N=1,044) published in Diabetes Care found that each 1% rise in HbA1c above 7% was associated with a 17% increase in wound complication risk at 90 days post-surgery (OR 1.17, 95% CI 1.09 to 1.26, P<0.001). [21]

Cardiovascular Risk Stratification at 12 Months

Major surgery induces a pro-inflammatory, pro-thrombotic state that may persist for months. Patients who underwent cardiac, vascular, or major abdominal surgery carry elevated cardiovascular event risk in the 12 months following the procedure.

The ACC/AHA 2014 guideline on perioperative cardiovascular evaluation recommends continuing beta-blockers and statins initiated perioperatively. [22] At the 12-month visit, confirm:

• Statin therapy is ongoing if prescribed pre-operatively.
• Blood pressure is at goal (<130/80 mmHg per ACC/AHA 2017).
• Aspirin or antiplatelet therapy status is documented.

A NEJM study of 15,133 non-cardiac surgery patients (POISE-2 trial) found aspirin did not reduce major adverse cardiovascular events but did increase major bleeding, reinforcing the need for individualized antiplatelet decisions at annual review. [23]

Rehabilitation and Return-to-Activity Milestones

Functional return-to-activity benchmarks should be confirmed or revised at the 12-month visit.

Strength and Conditioning

Patients who underwent orthopedic surgery should meet the following benchmarks by 12 months:

• Knee replacement: Timed Up and Go (TUG) test <12 seconds.
• Hip replacement: single-leg stance >10 seconds on operative side.
• Spinal fusion: return to light aerobic activity without radicular symptom reproduction.

Physical therapy records should be reviewed. Patients who did not complete at least 12 weeks of structured post-operative PT show meaningfully worse functional outcomes at 2 years per a 2020 JAMA Orthopedics study (N=467, P = 0.003). [24]

Return-to-Work Assessment

Work capacity depends on job classification. The treating surgeon's return-to-work documentation should be cross-referenced against current functional status. If discrepancies exist, an occupational therapy functional capacity evaluation is appropriate.

Putting It All Together: The Annual Evaluation Visit Structure

A practical 45-minute annual visit structure:

1. Intake (5 min): PRO survey (PROMIS-10 or SF-36) completed in waiting room.
2. Structured history (10 min): Pain NRS, analgesic burden, off-label peptide use, nutritional review.
3. Physical exam (10 min): Wound inspection with photos, gait speed, handgrip, BP, weight, BMI.
4. Lab review (5 min): CBC, CMP, CRP, ferritin, 25-OH vitamin D, HbA1c, albumin, ± testosterone.
5. Psychological screen (5 min): PHQ-9, GAD-7, ± MoCA if age >60.
6. Shared decision-making (10 min): Review findings, adjust medications, order additional imaging if warranted, update rehabilitation plan.

For patients using compounded peptides, add 5 minutes to the shared decision-making block to review the documentation framework above and counsel on the current state of human evidence.

The ACS NSQIP Participant Use Data File, updated annually, benchmarks your patient outcomes against national averages across 170+ variables. Submitting cases to NSQIP creates an institutional feedback loop that directly informs annual evaluation protocols. [1]